Note: The 15% and 8% figures in the first passage match the DME columns of Table 1. In the wet AMD trials (TENAYA and LUCERNE) the Table 1 rates were 3% for cataract and 7% for conjunctival hemorrhage. Table 1 columns are VABYSMO in AMD (N=664), DME (N=1,262), and RVO (N=641), then aflibercept in AMD (N=662), DME (N=625), and RVO (N=635), in that order; the AMD columns are the wet AMD trials (TENAYA and LUCERNE).